Linita

Generic

Linagliptin

 

Indications

LinitarM is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

 

Pharmacology

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor,which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1 ) and glucose-dependent insulinotropic polypeptide (GlP), are released by the intestine throughout the day, and levels are increased in response to a meal.These hormones are rapidly inactivated by the enzyme, DPP-4.The incretins are part of an endogenous system involved in the physiolog ic reg u lation of gl ucose homeostasis.When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. By increasing and proionging active incretin levels, Linitagliptin increases insulin release and decreases glucagon ievels in the circulation in a glucose-dependent manner,

 

Dosage & Administration

The recommended dose of LinitaTM is 5 mg once daily. No dosage administration is requiredfor hepatic or kidney impaired patients.

 

Interaction

Linagliptin is a mild competitive and weak to moderate mechanism-based inhibitor of the CYP isozyme CYP3A4, however it has no effect on the other CYP isozymes. The likelihood of clinically important interactions between linagliptin and other medical drugs is minimal, and in clinical investigations, linagliptin had no clinically relevant influence on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin, or phenytoin.

 

Side Effects

Side effects includes: Hypoglycemia, headache, drowsiness, weakness, dizziness, confusion, irritability, hu nget fast heart beat, sweati ng. 5tuffy or run ny nose and sore th roat.

 

Pregnancy & Lactation

Pregnancy: Pregnancy Category-B.There are no adequate and well-controlled studies in pregnant women. Linagliptin tablets should be used during pregnancy only if clearly needed.

Nursing Mothers: lt is not known if Linagliptin passes into breast milk. Caution should be exercised when Linitagliptin is administered to a nursing woman.

 

Precautions & Warnings

When used with an lnsuiin Secretagogue (e.9., Sulfonylurea), consider lowering the dose of the lnsulin Secretagogue to reduce the risk of hypoglycemia.

 

Therapeutic Class

DPP-4 (Dipeptidyl Peptidase-4) Inhibitor.

 

Storage Conditions

Keep away from light & moisture. Store below 30'C. Keep out of the reach of the children.

 

Pharmaceutical Name

Square Pharmaceuticals Ltd.